1. A polygenic risk score derived from common variants of monogenic diabetes genes is associated with young-onset type 2 diabetes and cardiovascular-kidney complications.
- Author
-
O CK, Fan B, Tsoi STF, Tam CHT, Wan R, Lau ESH, Shi M, Lim CKP, Yu G, Ho JPY, Chow EYK, Kong APS, Ozaki R, So WY, Ma RCW, Luk AOY, and Chan JCN
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Genetic Predisposition to Disease genetics, Multifactorial Inheritance genetics, Age of Onset, Case-Control Studies, Cross-Sectional Studies, Prospective Studies, Risk Factors, Gene Frequency, Exome Sequencing, Polymorphism, Single Nucleotide genetics, Genetic Risk Score, Diabetes Mellitus, Type 2 genetics, Cardiovascular Diseases genetics, Cardiovascular Diseases epidemiology
- Abstract
Aims/hypothesis: Monogenic diabetes is caused by rare mutations in genes usually implicated in beta cell biology. Common variants of monogenic diabetes genes (MDG) may jointly influence the risk of young-onset type 2 diabetes (YOD, diagnosed before the age of 40 years) and cardiovascular and kidney events., Methods: Using whole-exome sequencing data, we constructed a weighted polygenic risk score (wPRS) consisting of 135 common variants (minor allele frequency >0.01) of 34 MDG based on r
2 >0.2 for linkage disequilibrium in a discovery case-control cohort of 453 adults with YOD (median [IQR] age 39.7 [34.9-46.9] years) and 405 without YOD (median [IQR] age 56.7 [50.3-61.0] years), followed by validation in an independent cross-sectional cohort with array-based genotyping for YOD and a prospective cohort of individuals with type 2 diabetes for cardiovascular and kidney events., Results: In the discovery cohort, the OR of the 135 common variants for YOD ranged from 1.00 to 2.61. In the validation cohort (920 YOD and 4910 non-YOD), top-10%-wPRS was associated with an OR of 1.42 (95% CI 1.03, 1.95, p=0.033) for YOD compared with bottom-10%-wPRS. In 2313 individuals with type 2 diabetes (median [IQR]: age 53.4 [45.4-61.7] years; disease duration 4.0 [1.0-9.0] years) observed for a median (IQR) of 17.5 (14.4-21.8) years, standardised wPRS was associated with increased HR for incident cardiovascular events (1.16 [95% CI 1.06, 1.27], p=0.001), kidney events (1.09 [95% CI 1.02, 1.16], p=0.013) and cardiovascular-kidney events (1.10 [95% CI 1.03, 1.16], p=0.003). Using the 'bottom-20%-wPRS plus baseline disease duration <5 years' group as referent, the 'top-20%-wPRS plus baseline disease duration 5 to <10 years' group had unadjusted and adjusted HR of 1.60 (95% CI 1.17, 2.19, p=0.003) and 1.62 (95% CI 1.16, 2.26, p=0.005), respectively, for cardiovascular-kidney events compared with 1.38 (95% CI 0.97, 1.98, p=0.075) and 1.06 (95% CI 0.72, 1.57, p=0.752) in the 'bottom-20%-wPRS plus baseline disease duration ≥10 years' group., Conclusions/interpretation: Common variants of MDG increased risk for YOD and cardiovascular-kidney events., Competing Interests: Acknowledgements: We thank all the involved research and clinical staff in the Hospital Authority and Department of Medicine and Therapeutics, the Chinese University of Hong Kong, for their professionalism and dedication. Special thanks are extended to all patients, their relatives and volunteers for participating in these studies. We are grateful to the support of the Hong Kong Hospital Authority. Some data in this manuscript were presented in the American Diabetes Association 84th Scientific Sessions in the form of a published abstract and a poster in 2024. Data availability: Due to local law and regulation, no data can be shared with external parties. Summary statistics may be shared upon reasonable request to the corresponding author. Funding: The study is funded by the Hong Kong Genome Institute, Hong Kong Government Health and Medical Research Fund Commissioned Research (CFS-CUHK2) and Research Grants Council Impact Research Fund. Author’s relationships and activities: JCNC has received research grants (through institutions) and/or honoraria for consultancy and/or giving lectures from Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Hua Medicine, Powder Pharmaceuticals, Merck Serono, MSD, Pfizer, Sanofi, Viatris and Zuellig Pharma. AOYL has served as an advisory committee member for AstraZeneca, Boehringer Ingelheim, Sanofi and Amgen, and has received research grants and travel grants from AstraZeneca, Boehringer Ingelheim, MSD, Novartis, Novo Nordisk, Sanofi and Amgen. RCWM has received research grants for clinical trials from AstraZeneca, Bayer, MSD, Novo Nordisk, Sanofi, Roche and Tricida and honoraria for consultancy or lectures from AstraZeneca and Boehringer Ingelheim. APSK has received research grants and/or speaker honoraria from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Serono, Nestle, Novo Nordisk and Sanofi. JCNC, WYS and RCWM hold patents for using biogenetic markers to predict risk of diabetes and its complications. JCNC, CKPL, RCWM and WYS are co-founders of GemVCare, a biotech start-up supported by the Technology Start-up Support Scheme for Universities of the Hong Kong Government Innovation and Technology Commission. RCWM is an advisory board member of the editorial board of Diabetologia. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work. Contribution statement: JCNC and AOYL conceptualised the research question. CKO and BF performed the data analysis. CKO, BF, JCNC, AOYL, STFT, CHTT, RW, ESHL, MS, CKPL, GY, JPYH, EYKC, APSK, RO, WYS and RCWM contributed to the interpretation of the data. CKO wrote the first draft. All authors critically reviewed the manuscript and approved the final version. JCNC is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis., (© 2024. The Author(s).)- Published
- 2025
- Full Text
- View/download PDF